Valuation : Dermata Therapeutics, Inc.

Market Cap 4.83M 4.16M 3.93M 3.57M 6.68M 461M 6.74M 46.74M 17.98M 234M 18.12M 17.73M 746M P/E 2026 *
-0.55x
P/E 2027 * -0.84x
Enterprise Value 4.83M 4.16M 3.93M 3.57M 6.68M 461M 6.74M 46.74M 17.98M 234M 18.12M 17.73M 746M EV / Sales 2026 *
48.3x
EV / Sales 2027 * 6.44x
Free-Float
72.65%
Yield 2026 *
-
Yield 2027 * -
1 day-0.83%
1 week-6.25%
Current month-6.98%
1 month+9.09%
6 months-9.77%
Current year-48.28%
1 week 1.18
Extreme 1.18
1.31
1 month 1.08
Extreme 1.08
1.72
Current year 0.95
Extreme 0.9509
4.66
1 year 0.95
Extreme 0.9509
6.22
3 years 0.95
Extreme 0.9509
175.5
5 years 0.95
Extreme 0.9509
16,679.99
10 years 0.95
Extreme 0.9509
16,679.99
Manager TitleAgeSince
Chief Executive Officer 67 2014-12-07
Director of Finance/CFO 48 2021-08-31
Investor Relations Contact - -
Director TitleAgeSince
Chairman 67 2021-03-31
Director/Board Member 77 2014-12-07
Director/Board Member 78 2016-09-19
Date Insider Type Main position Quantity % Market Cap. Importance
8/16/26 Free

Chief Financial Officer

306,120 10.7966%
2/17/26 Buy

General Counsel

1,000 0.0353%
1/2/26 Free

Director

2,500 0.0940%
Change 5-day change 1-year change 3-year change Capi.($)
-0.83%-6.25%-76.88%-99.27% 4.87M
-0.25%-0.96%+45.25%+102.76% 68.52B
-1.09%-4.97%+31.10%+76.56% 62.88B
-1.18%+0.51%-13.53%+384.69% 28.13B
-2.74%-3.53%+26.13%+13.50% 25.56B
-1.76%-7.14%-5.57%-19.75% 24.65B
-2.39%-4.23%+18.42%-20.95% 19.81B
-1.86%+1.15%+205.44%+353.89% 17.69B
-1.37%-3.77%-9.38%+528.34% 14.66B
-1.54%-1.88%+50.03%+159.75% 14.45B
Average -1.50%-1.74%+27.10%+147.95% 27.64B
Weighted average by Cap. -1.28%-1.41%+35.43%+139.07%

Financials

2026 *2027 *
Net sales 100K 86.14K 81.33K 74.02K 138K 9.54M 140K 968K 373K 4.86M 376K 367K 15.46M 750K 646K 610K 555K 1.04M 71.58M 1.05M 7.26M 2.79M 36.43M 2.82M 2.75M 116M
Net income -11.08M -9.55M -9.01M -8.2M -15.34M -1.06B -15.48M -107M -41.28M -538M -41.62M -40.7M -1.71B -13.78M -11.87M -11.21M -10.2M -19.07M -1.32B -19.25M -133M -51.34M -669M -51.76M -50.62M -2.13B
Net Debt - -
Logo Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Employees
9
Date Price Change Volume
26-09-10 US$1.200 -0.83% 15,923
26-09-09 US$1.210 -3.20% 18,413
26-09-08 US$1.250 +3.31% 51,184
26-09-04 US$1.210 -1.63% 40,555
26-09-03 US$1.230 -3.91% 101,903
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.200USD
Average target price
4.000USD
Spread / Average Target
+233.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DRMA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!